Use casesManufacturers
See supply stress earlier. Protect margin longer.
For manufacturers of generic, branded, niche and specialist medicines. See supply pressure, pricing movement and demand shifts around your molecules earlier, so stock and pricing decisions are proportionate rather than reactive.
Who this is for
Commercial, supply chain, pricing and regulatory teams, and the boards they report to.
High-volume generics
Markets that oscillate: oversupply compresses pricing below viable cost, exits follow, then a sharp correction.
Seeing the cycle turn across a whole portfolio; for those who sell direct to pharmacy, the same view their customers rely on.
Niche & legacy
Few SKUs, each commercially significant. Thin margin most of the year, short windows of dislocation.
Acting inside those windows on stock and price, and negotiating with evidence.
Pharma / branded
A brand sits within a wider market of alternatives, competitor supply and moving prices.
Visibility of supply pressure, pricing movement and competitive context around the brand and its alternatives.
Biotech
Smaller or newer portfolios, often without established internal market data.
An external view of the supply market around their therapy area, as context for launch, partnering and supply planning.
The challenge
The challenge is not just visibility. It is acting before the window closes.
Official shortage notifications tend to arrive after disruption is already under way. By the time a shortage is formalised in the UK, the window for proportionate stock and pricing decisions has narrowed.
The signals that come first exist, but they are fragmented across markets and sources, so decisions fall back on internal forecasts, informal intelligence and competitor rumour.
These markets don't drift. They oscillate.
The generics pricing cycle
- Oversupply
- Price compression
- Manufacturers exit
- Supply falls short
- Price and concession movement
How MedSupply Intelligence helps
Supply and pricing, seen together. Earlier.
MedSupply Intelligence brings pricing, availability, supply and risk signals together around each medicine, including pressure at the active-ingredient level that a single product’s data will not show. Commercial, supply and regulatory teams work from the same view.
What it is notA sourcing platform, a stockpiling trigger, a replacement for your supplier relationships, or a guarantee of pricing outcome.
Compare our productsEight decisions. Earlier evidence.
Detect supply stress before formal shortageSupply risk
Disruption usually shows in the market before it is declared. Seeing that pressure earlier gives time to prepare stock and pricing proportionately, and to answer regulatory enquiries with evidence rather than in reaction.
Supports
- Stock preparation
- Pricing strategy
- Regulatory responses
Anticipate demand shiftsDemand
Many niche and legacy medicines sit dormant for most of the year, then demand lifts when supply falters elsewhere. In high-volume markets, a competitor exit moves volume quickly. Earlier visibility of that strain helps you have stock and pricing in position.
In thin markets, the spike matters more than the baseline.
Supports
- Stock release timing
- Pricing for short-term uplift
- Capacity planning
Understand pricing pressurePricing
See how market pricing is moving around a medicine, alongside the supply conditions behind it, rather than relying on current rates alone. In high-volume generics this means seeing where compression and correction are under way across the portfolio.
Supports
- Price changes
- Avoiding premature price drops
- Portfolio pricing review
Protect margin and portfolio positionMargin
In thin markets, buyers often negotiate from more market data than the manufacturer holds. Independent visibility helps separate genuine structural pressure from selective pricing leverage, and isolated price dumping from a systemic shift.
Supports
- Negotiation
- Margin defence
- Deciding when to hold price
Plan strategic stockInventory
Holding inventory in low-volume markets ties up capital; releasing it too early or too late erodes value. Combining supply and pricing movement helps align stock release with market conditions rather than internal assumptions.
Supports
- Working capital
- Write-down risk
- Release timing
Support commercial and S&OP decisionsRisk context
One supplier going out of stock does not always mean a market-wide shortage. Seeing signals across countries and suppliers helps teams tell isolated disruption from broad pressure, and avoid over-committing stock or panic pricing.
“Sometimes a shortage is not a shortage. It is someone hearing a rumour.”
Supports
- S&OP
- Proportionate responses
- Supply and commercial alignment
Assess tariff and concession exposureTariff risk
Drug Tariff and price concession movement usually follows changes in supply and market pricing. Seeing those conditions together gives time to prepare for concession changes and reduces exposure to unexpected tariff drops.
Supports
- Price adjustment timing
- Concession preparation
- Margin planning
Strengthen internal decision makingGovernance
Commercial, regulatory and supply teams often read fragmented signals differently. A single, evidence-based view supports alignment, helps justify strategy internally and gives board-level stakeholders a structured picture of market conditions.
Supports
- Cross-functional alignment
- Board reporting
- Internal justification
MedSupply Intelligence brings together supply, availability, pricing and risk signals to give earlier visibility of emerging market pressure and changing conditions.
Because in thin markets, timing is everything.